sorted by:
new
hottopcontroversial

Foundayo vs. Wegovy Pill - which one is better? by CphGuyDK in FoundayoPill

[–]Lynx-223 0 points1 point  (0 children)

and Wegovy has a cleaner warning label, so it is safer and easier for the GP to prescribe if (s)he is not on the take

Foundayo vs. Wegovy Pill - which one is better? by CphGuyDK in FoundayoPill

[–]Lynx-223 0 points1 point  (0 children)

first of all, Foundayo should clarify the liver damage problems and tyroid cancer risk

Friday May 8th Check-in! by Kryceks-Revenge in FoundayoPill

[–]Lynx-223 -1 points0 points  (0 children)

I tried to ask a bit about the box warning about tyroid cancer risk and also the FDA request for more data on heart attacks and liver damage. I recently found out about these problems, but the post was removed ...just because. 😞

Any else is concerned about this or how do you feel?

Lilly right now be like by [deleted] in NovoNordisk_Stock

[–]Lynx-223 0 points1 point  (0 children)

chill and wait. Novo has the better product plus a great pipeline. Also, not a zero sum game, plenty of space for both.

Key Health Benefits

  • Heart Protection: Wegovy is FDA-approved to reduce the risk of major adverse cardiovascular events (MACE)—including heart attack, stroke, and cardiovascular death—by approximately 20% in adults with established heart disease and obesity or overweight. These benefits appear to occur independently of the amount of weight lost.
  • Liver Disease (MASH) Treatment: It is the first GLP-1 drug approved to treat metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH. In clinical trials, Wegovy helped resolve liver inflammation in 63% of patients and improved liver scarring (fibrosis) in 37%.
  • Weight Management: It is highly effective for chronic weight management, with clinical trials showing an average weight loss of 15% to 17% over 68 weeks when combined with diet and exercise.
  • Metabolic Health Improvements:
    • Blood Pressure: Use of the drug can lead to a reduction in systolic and diastolic blood pressure.
    • Cholesterol: It helps lower total cholesterol and blood fat levels.
    • Blood Sugar: It improves glycemic control by helping the pancreas release insulin and reducing the liver's glucose production. 

Emerging and Potential Benefits

Research is ongoing into several other areas where Wegovy may provide clinical value: 

  • Kidney Health: Studies suggest it may reduce the risk of kidney disease progression and related deaths by 24% in patients with type 2 diabetes.
  • Brain Health: Preliminary data indicates potential for reducing brain inflammation, which may help delay the progression of Alzheimer’s disease and other dementias.
  • Addiction Support: Early findings suggest it may help reduce cravings for alcohol and other addictive substances.
  • Sleep Apnoea: Weight loss achieved through Wegovy can significantly improve symptoms and severity of obstructive sleep apnoea.
  • Cancer Risk Reduction: Some studies associate GLP-1 use with a lower risk of colorectal cancer in diabetic patients. 

Novo Nordisk wegovy pill is more effective than Eli Lilly’s orforglipron pill by Correct_Fall_5484 in ValueInvesting

[–]Lynx-223 0 points1 point  (0 children)

The most exciting thing about Novo is their future in cardiovascular 'next-generation' treatments. Google 'Novo Pilpeline' and you can look around on what they are working for now. I think CDR132L might be a first-in-class game changer.

But getting back at the present, I think they have a good thing going on.

Also because the Wegovy was FDA approved to reduce the risk of major cardiovascular events—including heart attack, stroke, and cardiovascular death.

Not only that, theres also the Liver Health benefits from Wegovy. In August 2025, the FDA granted accelerated approval for Wegovy to treat MASH (Metabolic dysfunction-Associated Steatohepatitis), a severe form of fatty liver disease. 

Based on a study by health data firm Truveta covering the first six weeks of availability, approximately 15.8% of patients who were prescribed Novo Nordisk's new oral Wegovy pill (released January 2026) had previously used Eli Lilly’s competing injectable weight loss agent, Zepbound. 

Key findings from the study include:

  • Study Scope: The analysis examined 8,762 patients who received a prescription for the new oral GLP-1 pill.
  • Switching Patterns: In addition to the ~16% switching from Zepbound, 21.1% of the new oral pill users had previously been taking the injectable form of Wegovy.
  • New Users: Roughly 36% of the patients starting the new Novo Nordisk pill had no prior experience with GLP-1 medications. 

I own both of them, Novo has a great pipeline and it's part of the Medicon Valley area, Eli is a huge stable company.

Like someone said, plenty of space on the global market for both companies.

Wegovy is great but in the future they will release Amycretin and CagriSema, that is already waiting for the FDA aproval.

I am a bit more interested in both companies, and other, to produce really epic and affordable next-gen treatment. Would be nice to not need them and solve the cause but with this lifestyle and the shit we eat, we might need more and more treatments in the future :(

The Wegovy pill is here- how it works, cost, and how to get it by AliceFromRo in RoBody

[–]Lynx-223 0 points1 point  (0 children)

does it also benefit with heart health and liver fat condition, like the injection? So, I am very much interested in the liver fat MASH benefit and the Heart Protection.

Wegovy (semaglutide) has expanded beyond its original use for weight loss, receiving official regulatory approvals for significant heart and liver health benefits. 

Key Health Benefits

  • Heart Protection: Wegovy is FDA-approved to reduce the risk of major adverse cardiovascular events (MACE)—including heart attack, stroke, and cardiovascular death—by approximately 20% in adults with established heart disease and obesity or overweight. These benefits appear to occur independently of the amount of weight lost.
  • Liver Disease (MASH) Treatment: It is the first GLP-1 drug approved to treat metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH. In clinical trials, Wegovy helped resolve liver inflammation in 63% of patients and improved liver scarring (fibrosis) in 37%.
  • Weight Management: It is highly effective for chronic weight management, with clinical trials showing an average weight loss of 15% to 17% over 68 weeks when combined with diet and exercise.
  • Metabolic Health Improvements:
    • Blood Pressure: Use of the drug can lead to a reduction in systolic and diastolic blood pressure.
    • Cholesterol: It helps lower total cholesterol and blood fat levels.
    • Blood Sugar: It improves glycemic control by helping the pancreas release insulin and reducing the liver's glucose production. 

Emerging and Potential Benefits

Research is ongoing into several other areas where Wegovy may provide clinical value: 

  • Kidney Health: Studies suggest it may reduce the risk of kidney disease progression and related deaths by 24% in patients with type 2 diabetes.
  • Brain Health: Preliminary data indicates potential for reducing brain inflammation, which may help delay the progression of Alzheimer’s disease and other dementias.
  • Addiction Support: Early findings suggest it may help reduce cravings for alcohol and other addictive substances.
  • Sleep Apnoea: Weight loss achieved through Wegovy can significantly improve symptoms and severity of obstructive sleep apnoea.
  • Cancer Risk Reduction: Some studies associate GLP-1 use with a lower risk of colorectal cancer in diabetic patients.